Q3 Revenue Jumps 36% to $361M, 2026 Guidance Raised on Shield Momentum
GH has more than doubled off its 52-week low of $74.55 on elevated volume (2.0× avg).
Summary
Guardant beat its own trajectory with Q3 revenue of $361.0 million, up 36% year over year, and lifted full-year 2026 revenue guidance to $1.36-$1.37 billion from $1.34-$1.36 billion. Screening is the engine: Shield revenue hit $67.6 million, up 180%, on 83,000 tests versus 24,000 a year ago, and management raised the screening outlook to $233-$238 million from $218-$230 million. Oncology grew 25% to $231.3 million with test volume up 58%. The offset is spending — non-GAAP operating expenses guidance rose to $1.105-$1.125 billion and free cash flow burn guidance widened to $205-$220 million from $195-$205 million, even as the non-GAAP net loss per share narrowed to $0.29 from $0.39 and the GAAP loss per share came in at 93 cents. This follows the November 3rd 8-K granting co-CEOs performance stock units tied to relative total shareholder return, aligning management pay with the stock. The quarter also carried regulatory wins: FDA approval of Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH and for INLURIYO plus VERZENIO, plus a PMA submission for Guardant360 Tissue. Watch whether the higher opex and cash burn get questioned on the 4:30 pm ET call against the raised revenue line.
At the time of this announcement, GH was trading at $159.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.6B. The 52-week trading range was $74.55 to $191.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.